Unigene Laboratories

{{Short description |Defunct American biopharmaceutical company that focused on peptides}}

{{more citations needed |date=March 2012}}

{{Infobox company

| name = Unigene Laboratories

| logo =

| type = Public

| traded_as = {{OTC Pink |type=noinfo |UGNEQ }}

| industry = Biotechnology

| founded = {{Start date |1980}}

| defunct = {{End date |2023|07|02}}

| fate = Bankrupt

| hq_location_city = New Jersey

| hq_location_country = United States

| key_people = {{UBL |Ashleigh Palmer (CEO) |Gregory T. Mayes, Esq. (Vice President) |Nozer Mehta (Vice President) |Paul Shields (Vice President) }}

| products = Research and development of peptides for medical purposes

| num_employees = 53

| num_employees_year = 2020

| website = {{URL|http://www.unigene.com}} {{deadlink|date=February 2025}}

}}

Unigene Laboratories was an American biopharmaceutical company, engaged in the research and development of peptides for medical purposes. The company was founded in 1980 and is located in New Jersey.{{cite web |url=https://pitchbook.com/profiles/company/41215-06#overview |title=Unigene Laboratories Overview |publisher=Pitchbook |access-date=February 21, 2025 }}{{cite news |url=https://www.genengnews.com/news/unigene-drops-a-third-of-its-staff-and-restructures-to-achieve-2010-savings-of-9-10m/ |title=Unigene Drops a Third of Its Staff and Restructures to Achieve 2010 Savings of $9–10M |date=December 9, 2009 |publisher=Genetic Engineering & Biotechnology News }}

The company's primary focus is on the development of calcitonin and related peptides for the treatment of osteoporosis. The company has licensed worldwide rights to its oral parathyroid hormone ("PTH") to GlaxoSmithKline.{{cite news |url=https://www.genengnews.com/topics/translational-medicine/unigene-divests-site-directed-bone-growth-patents-to-kieran-murphy/ |title=Unigene Divests Site-Directed Bone Growth Patents to Kieran Murphy |date=September 21, 2011 |publisher=Genetic Engineering & Biotechnology News }}{{cite news |url=https://www.nytimes.com/topic/company/unigene-laboratories-inc |title=GlaxoSmithKline to pay $420 Million for drug rights |date=April 16, 2002 |publisher=New York Times }}

Unigene filed for Chapter 7 bankruptcy on July 2, 2013 in the United States Bankruptcy Court of the District of New Jersey. The Chapter 7 case is being administered under case No. 13-24696.